私有化折戟,复宏汉霖恐失最佳机会

医曜
14 Feb

本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。反对比例超出10%,复宏汉霖私有化最终以失败告终。回顾港股18A的发展轨迹,交织着机遇与争议,每一家企业的重大抉择,都如同在书写一部扣人心弦的商业史诗,情节跌宕起伏,结局充满未知。复宏汉霖的私有化失败,绝对是其中令人瞩目的关键节点,留下了浓墨重彩的深刻印记。近年来,港股市场的持续低迷,恒生医疗保健指数连续四年下行,创新药企业的估值被...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10